The Association of Nicotinamide Phosphoribosyltransferase Polymorphism with Markers of Hepatic Injury and De Novo Lipogenesis in Nonalcoholic Fatty Liver Disease

Authors Information
Article Notes and Dates
To Cite : Amirkalali B, Sohrabi M R, Rahimi-Moghaddam P, Esrafily A, Gholami A, et al. The Association of Nicotinamide Phosphoribosyltransferase Polymorphism with Markers of Hepatic Injury and De Novo Lipogenesis in Nonalcoholic Fatty Liver Disease, Hepat Mon. 2017 ;17(6):e13570. doi: 10.5812/hepatmon.13570.
Copyright: Copyright © 2017, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol. 2011; 9(6): 524-530 e1[DOI][PubMed]
  • 2. Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013; 28 Suppl 1: 11-7[DOI][PubMed]
  • 3. Ostovaneh MR, Zamani F, Sharafkhah M, Ansari-Moghaddam A, Akhavan Khaleghi N, Saeedian FS, et al. Prevalence of metabolic syndrome in Amol and Zahedan, Iran: a population based study. Arch Iran Med. 2014; 17(7): 477-82[PubMed]
  • 4. Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010; 9: 42[DOI][PubMed]
  • 5. Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009; 9(4): 782-93[DOI][PubMed]
  • 6. Turati F, Talamini R, Pelucchi C, Polesel J, Franceschi S, Crispo A, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer. 2013; 108(1): 222-8[DOI][PubMed]
  • 7. Lee JJ, Lambert JE, Hovhannisyan Y, Ramos-Roman MA, Trombold JR, Wagner DA, et al. Palmitoleic acid is elevated in fatty liver disease and reflects hepatic lipogenesis. Am J Clin Nutr. 2015; 101(1): 34-43[DOI][PubMed]
  • 8. Donnelly KL, Smith CI, Schwarzenberg SJ, Jessurun J, Boldt MD, Parks EJ. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115(5): 1343-51[DOI][PubMed]
  • 9. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol. 2014; 7: 221-39[DOI][PubMed]
  • 10. Hallows WC, Lee S, Denu JM. Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases. Proc Natl Acad Sci U S A. 2006; 103(27): 10230-5[DOI][PubMed]
  • 11. Samal B, Sun Y, Stearns G, Xie C, Suggs S, McNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colony-enhancing factor. Mol Cell Biol. 1994; 14(2): 1431-7[DOI][PubMed]
  • 12. Genc H, Dogru T, Kara M, Tapan S, Ercin CN, Acikel C, et al. Association of plasma visfatin with hepatic and systemic inflammation in nonalcoholic fatty liver disease. Ann Hepatol. 2013; 12(4): 548-55[PubMed]
  • 13. Bekaert M, Verhelst X, Geerts A, Lapauw B, Calders P. Association of recently described adipokines with liver histology in biopsy-proven non-alcoholic fatty liver disease: a systematic review. Obes Rev. 2016; 17(1): 68-80[DOI][PubMed]
  • 14. Yan JJ, Tang NP, Tang JJ, Jia EZ, Wang MW, Wang QM, et al. Genetic variant in visfatin gene promoter is associated with decreased risk of coronary artery disease in a Chinese population. Clin Chim Acta. 2010; 411(1-2): 26-30[DOI][PubMed]
  • 15. Bailey SD, Loredo-Osti JC, Lepage P, Faith J, Fontaine J, Desbiens KM, et al. Common polymorphisms in the promoter of the visfatin gene (PBEF1) influence plasma insulin levels in a French-Canadian population. Diabetes. 2006; 55(10): 2896-902[DOI][PubMed]
  • 16. Hossein-nezhad A, Hosseinzadeh-Attar M, Najmafshar A, Jafari N, Rahmani M, Larijani B. Relationship between genotype and serum levels of adipokines and bone mineral density in type 2 diabetes mellitus patients. J Diabetes Metab Disord. 2009; 8: 77-86
  • 17. Mirzaei K, Hossein-Nezhad A, Javad Hosseinzadeh-Attar M, Jafari N, Najmafshar A, Mohammadzadeh N, et al. Visfatin genotype may modify the insulin resistance and lipid profile in type 2 diabetes patients. Minerva Endocrinol. 2009; 34(4): 273-9[PubMed]
  • 18. MacLaren R, Cui W, Cianflone K. Visfatin expression is hormonally regulated by metabolic and sex hormones in 3T3-L1 pre-adipocytes and adipocytes. Diabetes Obes Metab. 2007; 9(4): 490-7[DOI][PubMed]
  • 19. Zhou J, Seidel ER. Estrogens induce visfatin expression in 3T3-L1 cells. Peptides. 2010; 31(2): 271-4[DOI][PubMed]
  • 20. Sasso M, Tengher-Barna I, Ziol M, Miette V, Fournier C, Sandrin L, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. J Viral Hepat. 2012; 19(4): 244-53[DOI][PubMed]
  • 21. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003; 29(12): 1705-13[DOI][PubMed]
  • 22. Sanyal AJ, American Gastroenterological A. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(5): 1705-25[DOI][PubMed]
  • 23. Hudgins LC, Hellerstein M, Seidman C, Neese R, Diakun J, Hirsch J. Human fatty acid synthesis is stimulated by a eucaloric low fat, high carbohydrate diet. J Clin Invest. 1996; 97(9): 2081-91[DOI][PubMed]
  • 24. Esmaillzadeh A, Mirmiran P, Azizi F. Whole-grain intake and the prevalence of hypertriglyceridemic waist phenotype in Tehranian adults. Am J Clin Nutr. 2005; 81(1): 55-63[PubMed]
  • 25. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003; 35(8): 1381-95[DOI][PubMed]
  • 26. McDowell MA, Fryar CD, Hirsch R, Ogden CL. Anthropometric reference data for children and adults: US population, 1999–2002. Adv Data. 2005; 361(361): 1-5
  • 27. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther. 2009; 30(11-12): 1103-9[DOI][PubMed]
  • 28. Chong MF, Hodson L, Bickerton AS, Roberts R, Neville M, Karpe F, et al. Parallel activation of de novo lipogenesis and stearoyl-CoA desaturase activity after 3 d of high-carbohydrate feeding. Am J Clin Nutr. 2008; 87(4): 817-23[PubMed]
  • 29. McKenzie JA. The influence of visfatin and visfatin gene polymorphisms on glucose and obesity-related variables and their responses to aerobic exercise training. 2008;
  • 30. Wang Y, Yan LL, WU JJ, Dong P, Zhang CH, Wang JH. Relationship between single nucleotide polymorphisms of visfatin and type 2 diabetes mellitus. Acad J Xian Jiaotong Univ. 2011; 4
  • 31. Mirzaei K, Hosseinzadeh MJ, Hossein-Nezhad A, Jafari N, Rahmani M. The association between diabetes evaluation criteria and promoter polymorphism on visfatin gen. Iran J Diab Metab. 2009; 8(3): 237-46
  • 32. Pan JJ, Fallon J, Michael B. Gender and racial differences in nonalcoholic fatty liver disease. World J Hepatol. 2014; 6(5): 274-83
  • 33. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol. 2013; 178(1): 38-45[DOI][PubMed]
  • 34. Tiniakos DG. Nonalcoholic fatty liver disease/nonalcoholic steatohepatitis: histological diagnostic criteria and scoring systems. Eur J Gastroenterol Hepatol. 2010; 22(6): 643-50[DOI][PubMed]
  • 35. Caldwell SH, Lee VD, Kleiner DE, Al-Osaimi AM, Argo CK, Northup PG, et al. NASH and cryptogenic cirrhosis: a histological analysis. Ann Hepatol. 2009; 8(4): 346-52[PubMed]
  • 36. Stumvoll M, Tschritter O, Fritsche A, Staiger H, Renn W, Weisser M, et al. Association of the T-G polymorphism in adiponectin (exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes. 2002; 51(1): 37-41[DOI][PubMed]
  • 37. Wu X, Cooper RS, Borecki I, Hanis C, Bray M, Lewis CE, et al. A combined analysis of genomewide linkage scans for body mass index from the National Heart, Lung, and Blood Institute Family Blood Pressure Program. Am J Hum Genet. 2002; 70(5): 1247-56[DOI][PubMed]
  • 38. Hellerstein MK, Schwarz JM, Neese RA. Regulation of hepatic de novo lipogenesis in humans. Annu Rev Nutr. 1996; 16: 523-57[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check